EPHA2 and non-small cell lung carcinoma: EphA2 facilitates malignant progression by mediating interactions between tumor cells and their microenvironment, including endothelial and immune cells (12), and is associated with poor clinical prognosis, particularly in non-small cell lung cancer (NSCLC) (13, 14).